

RECEIVED
CENTRAL FAX CENTER

JUN 29 2007

Docket No. UF-300XC2


Serial No. 10/666,191

2

In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Previously presented). A method for providing estrogen replacement therapy to a patient while minimizing undesirable side effects associated with estrogen treatment or therapy, wherein said method comprises administering to the patient an effective amount of a quinol that is converted to a biologically active estrogen compound *in vivo*, wherein the quinol has the general structure:



wherein R is selected from the group consisting of H and ethynyl.

2-7 (Canceled).

8 (Original). The method according to claim 1, further comprising administering the quinol by a route selected from the group consisting of oral, buccal, intramuscular, transdermal, intravenous, and subcutaneous.

9 (Canceled).

10 (Previously presented). The method according to claim 1, wherein the biologically active estrogen compounds are provided to the patient for the treatment of symptoms, diseases, or conditions associated with menopause, wherein the symptoms, diseases, or conditions associated with menopause is any one or more selected from the group consisting of: irregular period, hot flashes, increased risk of vaginal and/or bladder infection, urge incontinence, stress incontinence, fatigue, depression, loss of muscle mass, increased fat tissue, thinning and loss of skin elasticity, loss of bone tissue, and impaired cognition.

J:\uf300xc2\UF-300XC2-Famend.doc&DNM\h

3


Docket No. UF-300XC2
Serial No. 10/666,191

11 (Previously presented). The method according to claim 1, wherein the biologically active estrogen compounds are provided to the patient for the treatment of conditions associated with the bone, wherein the conditions associated with the bone is any one or more selected from the group consisting of: osteoporosis, osteomyelitis, ischemic bone disease, fibrous dysplasia, rickets, Cushing's syndrome and osteoarthritis.

12 (Previously presented). The method according to claim 1, wherein the biologically active estrogen compounds are provided to the patient for treatment of conditions associated with heart disease, wherein the conditions associated with heart disease is any one or more selected from the group consisting of: stroke, cardiac ischemia, myocardial infarction, chronic or acute heart failure, cardiac dysrhythmias, atrial fibrillation, paroxysmal tachycardia, ventricular fibrillation and congestive heart failure.

13 (Canceled).

14 (Previously presented). A quinol that is converted to a biologically active estrogen compound via enzyme catalyzed reduction, said quinol having the general structure



wherein

R is alkyl;

X is hydrogen;

Y is hydrogen; and

Z is hydrogen.

15-19 (Canceled).


J:\uf300xc2\uf-300XC2-Finend.doc\DNB\1

4

Docket No. UF-300XC2

Serial No. 10/666,191

20 (Previously presented). A pharmaceutical composition comprising a quinol that is converted to a biologically active estrogen compound via enzyme catalyzed reduction, wherein said composition further comprises a pharmaceutically acceptable carrier, wherein said quinol has the general structure:



wherein

R is alkyl;

X is hydrogen;

Y is hydrogen; and

Z is hydrogen.

21-29 (Canceled).

J:\uf300xc2\uf-300XC2-Famend.doc\DNV\la